Literature DB >> 2063951

Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance.

G W Anderson1, J A Rosebrock, A J Johnson, G B Jennings, C J Peters.   

Abstract

A congenic rat strain (WF.LEW) was derived from the susceptible Wistar-Furth (WF) (background strain) and the resistant LEW (donor strain) inbred strains and was used to evaluate the phenotypic expression of a dominant Mendelian gene that confers resistance to fatal hepatic disease caused by the ZH501 strain of Rift Valley fever virus (RVFV). Resistance to hepatic disease developed gradually with age, with full expression at approximately 10 weeks in the WF.LEW and LEW rat strains. The ZH501 strain caused fatal hepatitis in WF rats regardless of age. However, resistance to the SA75 RVFV strain (relatively non-pathogenic for adult rats), was age- and dose-dependent in both WF and LEW rats. The resistance gene transferred to the newly derived WF.LEW congenic rat strain appears to amplify age-dependent resistance of adult rats, resulting in protection against fatal hepatic disease caused by the virulent ZH501 strain. The congenic rat strain will be a valuable asset in elucidating the mechanism of resistance to Rift Valley fever virus governed by the dominant Mendelian gene.

Entities:  

Mesh:

Year:  1991        PMID: 2063951     DOI: 10.4269/ajtmh.1991.44.475

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

Review 1.  Biological transmission of arboviruses: reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends.

Authors:  Goro Kuno; Gwong-Jen J Chang
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

2.  The genetic basis for susceptibility to Rift Valley fever disease in MBT/Pas mice.

Authors:  S Tokuda; T Z Do Valle; L Batista; D Simon-Chazottes; L Guillemot; M Bouloy; M Flamand; X Montagutelli; J-J Panthier
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 3.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

4.  Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals.

Authors:  Brian H Bird; César G Albariño; Amy L Hartman; Bobbie Rae Erickson; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

5.  Host alternation is necessary to maintain the genome stability of rift valley fever virus.

Authors:  Sara Moutailler; Benjamin Roche; Jean-Michel Thiberge; Valérie Caro; François Rougeon; Anna-Bella Failloux
Journal:  PLoS Negl Trop Dis       Date:  2011-05-24

6.  Association of symptoms and severity of rift valley fever with genetic polymorphisms in human innate immune pathways.

Authors:  Amy G Hise; Zachary Traylor; Noémi B Hall; Laura J Sutherland; Saidi Dahir; Megan E Ermler; Samuel Muiruri; Eric M Muchiri; James W Kazura; A Desirée LaBeaud; Charles H King; Catherine M Stein
Journal:  PLoS Negl Trop Dis       Date:  2015-03-10

7.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

8.  Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus.

Authors:  Jacquelyn M Bales; Diana S Powell; Laura M Bethel; Douglas S Reed; Amy L Hartman
Journal:  Front Cell Infect Microbiol       Date:  2012-08-02       Impact factor: 5.293

9.  Predicting the mosquito species and vertebrate species involved in the theoretical transmission of Rift Valley fever virus in the United States.

Authors:  Andrew J Golnar; Michael J Turell; A Desiree LaBeaud; Rebekah C Kading; Gabriel L Hamer
Journal:  PLoS Negl Trop Dis       Date:  2014-09-11

10.  Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates.

Authors:  Darci R Smith; Sara C Johnston; Ashley Piper; Miriam Botto; Ginger Donnelly; Joshua Shamblin; César G Albariño; Lisa E Hensley; Connie Schmaljohn; Stuart T Nichol; Brian H Bird
Journal:  PLoS Negl Trop Dis       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.